(Total Views: 491)
Posted On: 05/15/2020 10:21:05 AM
Post# of 154115
TM1,
Yup, but, more importantly we get DATA and ascertain if the children's Kawasaki-like conditions is a RANTES problem as well.
We have a large advantage in that, we get IncellRx (Dr. Patterson) in our side. If he gets measurements (even from one child) will be able to understand what is the issue in the context of COVID.
It he determines that Leronlimab can cure or help with (very likely) is time o talk to FDA.
So, this is an effort to gather information and understand above all.
Yup, but, more importantly we get DATA and ascertain if the children's Kawasaki-like conditions is a RANTES problem as well.
We have a large advantage in that, we get IncellRx (Dr. Patterson) in our side. If he gets measurements (even from one child) will be able to understand what is the issue in the context of COVID.
It he determines that Leronlimab can cure or help with (very likely) is time o talk to FDA.
So, this is an effort to gather information and understand above all.
(0)
(0)
